Substituted phthalazines for inducing insulin secretion and protecting beta-cells
US9278098B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Oct 27, 2014 |
| Grant date | Mar 8, 2016 |
| Priority date | — |
| Expiry date | Oct 27, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D237/32
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Phthalazine analogs of a Lisofylline (LSF) and synthetic methods for preparation of such analogs are provided. Compounds of the invention have structural formula III:wherein 1) R3a is hydrogen and R3b is selected from C5-22alkyl, C2-22alkenyl, or C2-22alkynyl; or a pharmaceutically acceptable salt thereof; or 2) R3b is hydrogen and R3a is selected from C9alkyl, C15-22alkyl, C9-22alkenyl, or C2-22alkynyl; or a pharmaceutically acceptable salt thereof; or 3) R3a and R3b are the same or different and are selected from C9alkyl, C15-22alkyl, C4-22alkenyl, or C2-22alkynyl; or a pharmaceutically acceptable salt thereof. The analogs of LSF provided have the ability to protect cell viability, particularly the ability to protect pancreatic β-cells, to induce insulin secretion.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.